23,267.7
(6.85)
(0.02%)
30 Apr , 2026 | 04:14 PM
Open
23,191.95
Prev. Close
23,260.85
Market Cap.
₹18,16,873.43
Div Yield
0.68
PE
34.82
PB
34.82
23,054.85
23,375.1
Performance
One Week (%)
3.58
One Month (%)
4.62
One Year (%)
7.3
YTD (%)
5.67
Company Name | CMP | High | Low | Volume |
|---|---|---|---|---|
Abbott India Ltd | 25,435 | 25,485 | 25,250 | 4,669 |
Cipla Ltd | 1,309.6 | 1,329.8 | 1,305 | 13,70,336 |
J B Chemicals & Pharmaceuticals Ltd | 2,043.4 | 2,072.9 | 2,028.7 | 1,45,245 |
Dr Reddys Laboratories Ltd | 1,322.9 | 1,340.3 | 1,313.6 | 12,27,007 |
Lupin Ltd | 2,305.2 | 2,317.4 | 2,277.7 | 10,95,515 |
Torrent Pharmaceuticals Ltd | 4,185.1 | 4,234.7 | 4,146.1 | 2,78,059 |
Ipca Laboratories Ltd | 1,530.9 | 1,590 | 1,524.3 | 3,48,783 |
Sun Pharmaceutical Industries Ltd | 1,808.3 | 1,815 | 1,761.4 | 47,49,798 |
Aurobindo Pharma Ltd | 1,389.5 | 1,404 | 1,378.6 | 6,06,347 |
Wockhardt Ltd | 1,395.6 | 1,422 | 1,382 | 4,81,602 |
Ajanta Pharma Ltd | 2,822.7 | 2,843.8 | 2,790 | 59,221 |
Gland Pharma Ltd | 1,750.8 | 1,767.3 | 1,728.4 | 2,21,268 |
Biocon Ltd | 359.65 | 361.65 | 354.25 | 19,96,623 |
Alkem Laboratories Ltd | 5,400 | 5,435 | 5,291 | 1,51,866 |
Glenmark Pharmaceuticals Ltd | 2,406.3 | 2,455.9 | 2,385.6 | 7,92,796 |
Zydus Lifesciences Ltd | 891.9 | 915.4 | 890.4 | 9,86,154 |
Divis Laboratories Ltd | 6,502.5 | 6,547 | 6,429 | 3,79,741 |
Mankind Pharma Ltd | 2,246.7 | 2,266.8 | 2,217 | 1,87,564 |
Laurus Labs Ltd | 1,100.95 | 1,112.95 | 1,080 | 23,64,117 |
Piramal Pharma Ltd | 161.87 | 162.9 | 156.14 | 34,40,783 |
Benchmark indices closed in the red with Nifty at 24,044 and Sensex at 77,132, weighed down by global uncertainty, surging oil prices, and foreign investor outflows. While select stocks like Bajaj Auto and Bajaj Finance showed strength, sectors such as metals, PSU banks, and realty faced sharp declines in a risk-off market environment.
30 Apr 2026|05:07 PM
Vedanta stock saw a sharp 65–70% fall ahead of its 2026 demerger, but the drop is purely technical as the company splits into five new entities. Investors will receive shares in all new businesses, meaning no real value is lost—only redistributed.
30 Apr 2026|12:39 PM
After a strong rally, defence stocks have seen a noticeable correction, leaving investors concerned. This analysis breaks down the key factors behind the decline—from profit booking and valuation concerns to market sentiment shifts—and explains what it means for the sector’s future outlook.
30 Apr 2026|12:05 PM
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
